These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 24797183)

  • 21. Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies.
    Kayser S; Zucknick M; Döhner K; Krauter J; Köhne CH; Horst HA; Held G; von Lilienfeld-Toal M; Wilhelm S; Rummel M; Germing U; Götze K; Nachbaur D; Schlegelberger B; Göhring G; Späth D; Morlok C; Teleanu V; Ganser A; Döhner H; Schlenk RF;
    Blood; 2012 Jan; 119(2):551-8. PubMed ID: 22096250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of revised IPSS cytogenetic risk stratification and prognostic impact of monosomal karyotype in 783 patients with primary myelodysplastic syndromes.
    Gangat N; Patnaik MM; Begna K; Kourelis T; Knudson RA; Ketterling RP; Hodnefield JM; Hanson CA; Pardanani A; Tefferi A
    Am J Hematol; 2013 Aug; 88(8):690-3. PubMed ID: 23686868
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic impact of complex and/or monosomal karyotypes in post-transplant poor cytogenetic acute myeloid leukaemia: A quantitative approach.
    Jo T; Arai Y; Oshima S; Kondo T; Harada K; Uchida N; Doki N; Fukuda T; Tanaka M; Ozawa Y; Kuriyama T; Ikegame K; Katayama Y; Ota S; Ara T; Kawakita T; Onizuka M; Ichinohe T; Atsuta Y; Yanada M;
    Br J Haematol; 2023 Jul; 202(2):356-368. PubMed ID: 37211753
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation.
    Heuser M; Gabdoulline R; Löffeld P; Dobbernack V; Kreimeyer H; Pankratz M; Flintrop M; Liebich A; Klesse S; Panagiota V; Stadler M; Wichmann M; Shahswar R; Platzbecker U; Thiede C; Schroeder T; Kobbe G; Geffers R; Schlegelberger B; Göhring G; Kreipe HH; Germing U; Ganser A; Kröger N; Koenecke C; Thol F
    Ann Hematol; 2017 Aug; 96(8):1361-1372. PubMed ID: 28612220
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
    Gyurkocza B; Gutman J; Nemecek ER; Bar M; Milano F; Ramakrishnan A; Scott B; Fang M; Wood B; Pagel JM; Baumgart J; Delaney C; Maziarz RT; Sandmaier BM; Estey EH; Appelbaum FR; Storer BE; Deeg HJ
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):549-55. PubMed ID: 24440648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution.
    Bernasconi P; Klersy C; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Caresana M; Quarna J; Lazzarino M; Bernasconi C
    Leukemia; 2005 Aug; 19(8):1424-31. PubMed ID: 15920496
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Up-front allogeneic hematopoietic cell transplantation in acute myeloid leukemia arising from the myelodysplastic syndrome.
    Choi Y; Kim SD; Park YH; Lee JS; Kim DY; Lee JH; Lee KH; Seol M; Lee YS; Kang YA; Jeon M; Jung AR; Lee JH
    Acta Haematol; 2015; 133(2):183-92. PubMed ID: 25323649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.
    Morel P; Hebbar M; Lai JL; Duhamel A; Preudhomme C; Wattel E; Bauters F; Fenaux P
    Leukemia; 1993 Sep; 7(9):1315-23. PubMed ID: 8371581
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management.
    Garcia-Manero G; Chien KS; Montalban-Bravo G
    Am J Hematol; 2020 Nov; 95(11):1399-1420. PubMed ID: 32744763
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge.
    Schanz J; Tüchler H; Solé F; Mallo M; Luño E; Cervera J; Granada I; Hildebrandt B; Slovak ML; Ohyashiki K; Steidl C; Fonatsch C; Pfeilstöcker M; Nösslinger T; Valent P; Giagounidis A; Aul C; Lübbert M; Stauder R; Krieger O; Garcia-Manero G; Faderl S; Pierce S; Le Beau MM; Bennett JM; Greenberg P; Germing U; Haase D
    J Clin Oncol; 2012 Mar; 30(8):820-9. PubMed ID: 22331955
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Cytogenetic abnormalities of 50 MDS patients by FISH detection and conventional karyotype analysis].
    Gao DG; Li BT; Zhou LN; Chen H; Zhang B
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1190-4. PubMed ID: 24156432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party.
    Scheid C; de Wreede L; van Biezen A; Koenecke C; Göhring G; Volin L; Maertens J; Finke J; Passweg J; Beelen D; Cornelissen JJ; Itälä-Remes M; Chevallier P; Russell N; Petersen E; Milpied N; Richard Espiga C; Peniket A; Sierra J; Mufti G; Crawley C; Veelken JH; Ljungman P; Cahn JY; Alessandrino EP; de Witte T; Robin M; Kröger N
    Bone Marrow Transplant; 2017 Nov; 52(11):1519-1525. PubMed ID: 28892084
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Kongtim P; Parmar S; Milton DR; Perez JMR; Rondon G; Chen J; Chilkulwar AR; Al-Atrash G; Alousi A; Andersson BS; Im JS; Hosing CM; Bashir Q; Khouri I; Kebriaei P; Oran B; Popat U; Champlin R; Ciurea SO
    Bone Marrow Transplant; 2019 Jun; 54(6):839-848. PubMed ID: 30258129
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system.
    Schanz J; Steidl C; Fonatsch C; Pfeilstöcker M; Nösslinger T; Tuechler H; Valent P; Hildebrandt B; Giagounidis A; Aul C; Lübbert M; Stauder R; Krieger O; Garcia-Manero G; Kantarjian H; Germing U; Haase D; Estey E
    J Clin Oncol; 2011 May; 29(15):1963-70. PubMed ID: 21519021
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System.
    van Spronsen MF; Ossenkoppele GJ; Westers TM; van de Loosdrecht AA
    Eur J Cancer; 2016 Mar; 56():10-20. PubMed ID: 26798967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic Impact of Cytogenetic Evolution on the Outcome of Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia in Nonremission: A Single-Institute Analysis of 212 Recipients.
    Yuasa M; Yamamoto H; Mitsuki T; Kageyama K; Kaji D; Taya Y; Nishida A; Ishiwata K; Takagi S; Yamamoto G; Asano-Mori Y; Wake A; Koike Y; Makino S; Uchida N; Taniguchi S
    Biol Blood Marrow Transplant; 2020 Dec; 26(12):2262-2270. PubMed ID: 32871257
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bone Marrow WT1 Levels in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplasia: Clinically Relevant Time Points and 100 Copies Threshold Value.
    Nomdedéu JF; Esquirol A; Carricondo M; Pratcorona M; Hoyos M; Garrido A; Rubio M; Bussaglia E; García-Cadenas I; Estivill C; Brunet S; Martino R; Sierra J
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):55-63. PubMed ID: 28939453
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes.
    Solé F; Luño E; Sanzo C; Espinet B; Sanz GF; Cervera J; Calasanz MJ; Cigudosa JC; Millà F; Ribera JM; Bureo E; Marquez ML; Arranz E; Florensa L
    Haematologica; 2005 Sep; 90(9):1168-78. PubMed ID: 16154839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion.
    Garderet L; Ziagkos D; van Biezen A; Iacobelli S; Finke J; Maertens J; Volin L; Ljungman P; Chevallier P; Passweg J; Schaap N; Beelen D; Nagler A; Blaise D; Poiré X; Yakoub-Agha I; Lenhoff S; Craddock C; Schots R; Rambaldi A; Sanz J; Jindra P; Mufti GJ; Robin M; Kröger N
    Biol Blood Marrow Transplant; 2018 Mar; 24(3):507-513. PubMed ID: 29196078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcomes of patients with therapy-related AML/myelodysplastic syndrome (t-AML/MDS) following hematopoietic cell transplantation.
    Alam N; Atenafu EG; Kuruvilla J; Uhm J; Lipton JH; Messner HA; Kim DH; Seftel M; Gupta V
    Bone Marrow Transplant; 2015 Sep; 50(9):1180-6. PubMed ID: 26121109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.